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Abstract
Background: In the search for anticancer agents, a promising 17-b-estradiol metabolite, 2-methoxyestradiol (2ME2)
was found that exerts antiproliferative in vitro and in vivo activity. Since 2ME2 has limited biological accessibility and
rapid metabolic degradation, the purpose of this study was to investigate the in vitro influence exerted by an
analogue of 2ME2 namely 2-methoxyestradiol-bis-sulphamate (2MEBM) in a breast adenocarcinoma cell line (MCF-7).
Methods: This was conducted by investigating 2MEBM’s in vitro influence on cell cycle progression, mitochondrial
membrane potential and possible production of reactive oxygen species (ROS) generation. In vitro effects of
2MEBM on cell cycle progression was demonstrated by means of flow cytometry using propidium iodide.
Hydrogen peroxide and superoxide production was investigated using 2,7-dichlorofluorescein diacetate and
hydroethidine, respectively. The probable reduction in the mitochondrial membrane potential was demonstrated
using a MitoCapture™ kit.
Results: Cell cycle progression revealed the presence of a sub-G1 apoptotic peak. Reduction of mitochondrial
membrane potential after exposure to 2MEBM was demonstrated and an increase in ROS production was also
observed.
Conclusion: This study verified that 2MEBM exposure resulted in apoptosis induction, increased ROS production
and reduced mitochondrial membrane potential in a tumorigenic breast epithelial cell line. Data obtained from this
project contributes to the unravelling of the in vitro signal transduction of 2MEBM in tumorigenic cell lines.
Keywords: 2-methoxyestradiol-bis-sulphamate, cell cycle progression, reactive oxygen species, mitochondrial integ-
rity, apoptosis, autophagy
Introduction
2-Methoxyestradiol (2ME2), the major derivative of 2-
hydroxyestrogens is an endogenous inhibitor of breast
cancer development [1]. 2ME2 exerts its antiprolifera-
tive, antiangiogenic and anticancer in vitro and in vivo
activity in an estrogen receptor independent mode [1-3].
Antiproliferative effects were observed in the estrogen
receptor positive human breast adenocarcinoma cell line
(MCF-7), highly tumorigenic melanoma cell line (MDA-
MB-435) and the human cervical adenocarcinoma cell
line (HeLa). In addition, 2ME2 also inhibited in vivo
growth of xenografts generated from MDA-MB-435
melanoma cells, murine sarcoma cells (Meth A sarco-
mas), murine melanoma cells (B16 sarcomas) and the
human multiple myeloma KAS-6/1 cell line [3]. 2ME2
(patented as Panzem
®) is currently undergoing phase II
clinical trials as an anticancer drug for multiple mye-
loma [2], ovarian cancer [4], glioblastoma multiforme
[5], breast- and prostate cancer [6]. However, high doses
are needed (up to 6 g/day), since 2ME2 has limited bio-
logical accessibility due to the rapid inactivation of the
hydroxyl groups at positions C3/C17 by conjugation and
oxidation [7].
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of 2ME2 resulted in the chemical production of promis-
ing 2ME2 analogues. One of these analogues is 2-meth-
oxyestradiol-bis-sulphamate (2MEBM), a bis-
sulphamoylated derivative of 2ME2 that possesses anti-
proliferative and antitumor activity with enhanced bioa-
vailability [8-11]. In vitro human umbilical vein
endothelial cells (HUVEC) growth-inhibition assay stu-
dies indicated that 2MEBM is 60-fold more potent than
2ME2 as antiangioangenic agent [3] and tenfold more
potent than 2ME2 as an antiproliferative agent [3,12].
Increased potency is related to the additional sulphamate
group added to the precursor 2ME2 molecule [3,12].
Antiproliferative effects of 2MEBM have been
reported in tumour growth in nude mice bearing xeno-
grafts derived from MDA-MB-435 cells, estrogen recep-
tor positive human breast adenocarcinoma wild type cell
line (MCF-7wt), mitoxantrone resistant breast adenocar-
cinoma cell line (MCF-7 MR), drug resistant human
adenocarcinoma cell line (MCF-7 DOX40), prostate can-
cer cell line (LNACaP) and human umbilical vein
endothelial cells (HUVEC) [3,13-15]. 2MEBM induces a
G2/M arrest with reversible morphology change in der-
mal fibroblasts from the elongated fibroblast morphol-
ogy to a cobblestone, morphology with rounding of
cells, while the same treatment in human umbilical vein
endothelial cells did not induce morphological changes
or a G2/M arrest, indicating that the effects of 2MEBM
on growth is cell line dependent [16]. A G2/M arrest
followed by the induction of apoptosis was however
observed in cell lines including tumorigenic estrogen
receptor positive breast carcinoma cell line (MCF-7),
drug resistant human adenocarcinoma cell line (MCF-7
DOX40), mitoxantrone resistant breast adenocarcinoma
cell line (MCF-7 MR) and highly tumorigenic estrogen
receptor negative breast carcinoma cell line MDA-MB-
231 [8,17].
Since several questions remain regarding the in vitro
influence of 2MEBM, this study aimed to investigate
whether 2MEBM alters cell cycle progression and mito-
chondrial membrane integrity. The influence on reactive
oxygen species production in the tumorigenic breast
epithelial MCF-7 cell line was also studied.
Materials and methods
Materials
Cell line
MCF-7 is a tumorigenic adherent breast epithelial cell
line derived from metastatic sites in adenocarcinoma.
MCF-7 cells are able to process estradiol via cytoplasmic
estrogen receptors and are capable of forming domes.
MCF-7 cells were supplied by Highveld Biological (Pty)
Ltd. (Sandringham, South Africa).
Reagents
All required reagents of cell culture analytical grade
were purchased from Sigma (St. Louis, United States of
America) unless otherwise specified. Heat-inactivated
fetal calf serum (FCS), sterile cell culture flasks and
plates were purchased from Sterilab Services (Kempton
Park, Johannesburg, South Africa). Penicillin, streptomy-
cin and fungizone were obtained from Highveld Biologi-
cal (Pty) Ltd. (Sandringham, South Africa). 2,7-
Dichlorofluorescein diacetate and hydroethidine was
acquired from Sigma (St. Louis, United States of Amer-
ica). The MitoCapture ™ Mitochondrial apoptosis
detection kit was purchased from BIOCOM biotech
(Pty) Ltd. (Clubview, South Africa). Since 2MEBM is
not commercially available, it was synthesized by Profes-
sor Vleggaar from the Department of Chemistry (Uni-
versity of Pretoria, Pretoria, South Africa). The
fluorescence activated cell sorting (FACS) FC500 System
flow cytometer equipped with an air-cooled argon laser
excited at 488 nm was supplied by Beckman Coulter
South Africa (Pty) Ltd. (Pretoria, South Africa).
Cell culture
Cells were grown and maintained in 25 cm
2 tissue cul-
ture flasks in a humidified atmosphere at 37°C and 5%
CO2. MCF-7 cells were cultured in Dulbecco’s mini-
mum essential medium eagle (DMEM) and supplemen-
ted with 10% heat-inactivated FCS (56°C, 30 min), 100
U/ml penicillin G, 100 μg/ml streptomycin and fungi-
zone (250 μg/l).
General cell culture procedures for experiments
A stock solution of 2 × 10
-3M2 M E B Md i s s o l v e di n
dimethyl sulphoxide (DMSO) was prepared and diluted
with medium to the desired concentrations prior to
exposure of the cells. Medium of control cells was sup-
plemented with an equal volume of DMSO (vehicle
control cells). The DMSO content of the final dilutions
never exceeded 0.05% (v/v). Experiments were con-
ducted in 25 cm
2 cell culture flasks with exponentially
growing MCF-7 cells seeded at 1 × 10
6 cells per 25
cm
2 flask to a final volume of 5 ml of maintenance
medium. After a 24 h incubation period at 37°C to
allow for cell adherence, medium was discarded and
cells were exposed to 2MEBM. Previous data obtained
in our laboratory by means of crystal violet staining
revealed that the 50% growth inhibitory concentration
(IC50) of 2MEBM on the tumorigenic MCF-7 cell line
was found to be after 48 h of exposure and a concen-
tration a 0.4 μM [18,19]. All subsequent experiments
were thus performed at 48 h exposure period with a
0.4 μM 2MEBM on MCF-7 cells. Cells exposed to acti-
nomycin D with a concentration of 0.1 μg/ml in
growth medium for 48 h served as a positive control
for apoptosis.
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Cell cycle progression
Cell cycle distribution, G2/M block and the detection of
as u b - G 1 apoptotic peak were analysed by flow cytome-
try using propidium iodide DNA staining. After 48 h of
exposure to 0.4 μM 2MEBM, cells were trypsinized and
resuspended in 1 ml growth medium. 1 × 10
6 cells were
centrifuged for 5 min at 300 xg. The pellet resuspended
twice in ice-cold phosphate buffer solution (PBS). The
supernatant was discarded and the cells were resus-
pended in 200 μl of ice-cold PBS containing 0.1% FCS.
Ice-cold 70% ethanol (4 ml) was added in a drop wise
manner and cells were stored at 4°C for 24 h. After 24
h, cells were pelleted by centrifugation for 5 min. The
supernatant was removed and cells were resuspended in
1 ml of PBS containing propidium iodide (40 μg/ml)
and incubated at 37°C, 5% CO2 for 45 min. Subse-
quently, cells were analysed by means of FACS FC500
System flow cytometer (Beckman Coulter South Africa
(Pty) Ltd) equipped with an air-cooled argon laser
excited at 488 nm. Cell cycle distributions were calcu-
lated from at least 10 000 cells and were analyzed
means of cyflogic version 1.2.1 software (Pertu Therho,
Turko, Finland) by assigning relative DNA content per
cell to sub-G1,G 1, S and G2/M fractions.
Mitochondrial membrane potential
Mitochondrial integrity was investigated by means of a
unique cationic dye, 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetra-
ethylbenzimidazolylcarbocyanine iodide. The MitoCap-
ture ™ mitochondrial kit provides quantitive apoptosis
information. Reduction of the mitochondrial membrane
potential is an early feature during apoptosis due to the
loss of the electrochemical gradient across the mito-
chondrial membrane [20]. Actinomycin D will be uti-
lised as a positive control for reductions in the
mitochondrial membrane [21]. After 48 h of exposure to
0.4 μM 2MEBM, cells were trypsinized and centrifuged
at 13 000 × g. Cells were resuspended in 1 ml of diluted
MitoCapture solution (1 μlM i t o C a p t u r e :1m lp r e -
warmed incubation buffer), incubated at a humidified
atmosphere (37°C, 5% CO2)f o r2 0m i na n ds u b s e -
quently centrifuged at 500 × g. After the supernatant
was discarded, cells were resuspended in 1 ml of pre-
warmed incubation buffer (37°C). Cells were analyzed
immediately after following the above-mentioned step
using fluorescence activated cell sorting (FACS) FC500
System flow cytometer (Beckman Coulter South Africa
(Pty) Ltd). Apoptotic cells were detected in the FITC
channel (usually FL1) showing diffused green fluores-
cence. Data from at least 10 000 cells were analyzed by
means of cyflogic version 1.2.1 software (Pertu Therho,
Turko, Finland).
Hydrogen peroxide measurement
Hydrogen peroxide (H2O2) generation was assessed
using 2,7-dichlorofluorescein diacetate (DCFDA), a non-
fluorescent probe, which, upon oxidation by ROS and
peroxides is converted to the highly fluorescent deriva-
tive 2,7-dichlorofluorescein (DCF). After 48 h of treat-
ment, cells were trypsinized and 1 × 10
6 cells were
resuspended in 1 ml PBS. Cells were incubated with 20
μM DCFDA for 25 min at 37
°C. Hydrogen peroxide (20
μM) was added 5 min prior to measurement as a posi-
tive control for DCF formation. DCF (FL1) fluorescence
was measured with a FACS FC500 System flow cyt-
ometer (Beckman Coulter South Africa (Pty) Ltd.)
equipped with an air-cooled argon laser excited at 488
nm. Data analysis from at least 10 000 cells were con-
ducted using cyflogic version 1.2.1 software (Pertu
Therho, Turko, Finland).
Superoxide measurement
Superoxide generation was assessed using hydroethi-
dine (HE). HE is oxidized by superoxide and not by
hydroxyl radicals, singlet O2,H 2O2 or nitrogen radi-
cals, to a red fluorescent compound. After 48 h of
treatment, cells were trypsinized and 1 × 10
6 cells
were resuspended in 1 ml PBS. Cells were incubated
with 10 μMH Ef o r1 5m i na t3 7
°C. The HE fluores-
cent product fluorescence (FL2) was measured using a
FACS FC500 System flow cytometer (Beckman Coulter
South Africa (Pty) Ltd.) equipped with an air-cooled
argon laser excited at 488 nm. The information gener-
ated from at least 10 000 cells were analyzed by means
of cyflogic version 1.2.1 software (Pertu Therho,
Turko, Finland).
Statistics
Measurement of FITC-, HE- and DCF-derived fluores-
cence was expressed as a ratio of the value measured for
the 2MEBM-treated cells compared to vehicle-treated
exposed cells (mean relative fluorescence). Flow cytome-
try analysis involved data from at least 10 000 events
that was repeated thrice where after a representative fig-
ure was chosen for each experiment.
Results
Cell cycle progression
DNA content analyses by means of flow cytometry
showed no increase of cells occupying the G2/M phase
in 2MEBM-treated cells compared to vehicle-treated
cells. However, a statistically significant increase was
observed in the sub-G1 population when compared to
the vehicle-treated cells. Furthermore, a reduction of
2MEBM-treated cells in the G1-phase was found when
compared to the vehicle-treated control (Figure 1A
and 1B).
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Flow cytometry analyses revealed a statistically insignifi-
cant reduction in the mitochondrial membrane potential
in the 2MEBM-treated cells when compared to vehicle-
treated cells and actinomycin D-treated cells (Figure 2A,
B and 2C). The latter is an indicator of apoptosis due to
the loss of the electrochemical gradient across the mito-
chondrial membrane.
Hydrogen peroxide
In order to investigate the hydrogen peroxide produc-
tion in 2MEBM-treated cells compared to vehicle-
treated cells, flow cytometry using DCFDA was
employed. A statistically insignificant increase in hydro-
gen peroxide was detected in the 2MEBM-treated cells
when compared to the vehicle-treated cells (Figure 3A
and 3B).
Superoxide measurement
Flow cytometry utilizing HE demonstrated the influence
of 2MEBM on superoxide production in MCF-7 cells.
The latter was increased in a statistically insignificant
manner in 2MEBM-treated cells when compared to the
vehicle-treated cells (Figure 4A and 4B).
Number
of
events
A B
Number
of
events
FL 3 Lin FL 3 Lin
0.95%
Sub-G1
Sub-G1
62.71%
14.02%
22.3%
G1
S
GM 2
G1
S
GM 2
41.16%
25.1%
11.18%
22.53%
Figure 1 Cell cycle histograms (FL3 Log representing propidium iodide detected by flow cytometry) revealed a statistical significant
sub-G1 apoptotic increase in 0.4 μM 2ME2BM-treated cells (B) when compared to vehicle-treated cells (A). However, no G2/M block was
observed in the 0.4 μM 2ME2BM-treated cells. A decrease in cells present in G1 was found in the 0.4 μM 2ME2BM-treated cells when compared
to the vehicle-treated cells.
A
Number
of
events
Number
of
events
B
Number
of
events
Number
of
events
98.26% viable 94.8% viable
1.73% non-viable 5.2% non-viable
FL 1 Log FL 1 Log
89.99% viable
10.01% non-viable
C
FL 1 Log
Number
of
events
Number
of
events
Figure 2 Mitochondrial membrane potential was investigated by means of flow cytometry using the,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide dye (FL1 Log represented the dye detected by the flow cytometry). A reduction in
mitochondrial membrane potential was observed in the 2ME2BM-treated cells (B) when compared to the vehicle-treated cells (A). Figure C
depicts MCF-7 cells exposed to actinomycin D which was used as the positive control for the reduction of the mitochondrial membrane
potential.
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As previously stated, 2MEBM holds therapeutic poten-
tial as an anticancer agent, since it exerts antiprolifera-
tive effects in vitro and inhibits tumour growth in vivo
[14]. In this article the effects of 2MEBM on the MCF-7
cell line was investigated by demonstrating the influence
of 2MEBM on cell cycle progression, membrane integ-
rity and possible production of reactive oxygen species
in order to suggests the types of cell death induced by
2MEBM.
Previous reports have indicated that 2MEBM induces
aG 2/M arrest followed by induction of apoptosis in cell
lines including MCF-7, MCF-7 DOX40, MCF-7 MR and
MDA-MB-231 [8,17]. In addition, 2MEBM caused a sig-
nificant apoptotic sub-G1 peak after 48 h. Day, et al
(2009) observed similar results where 24 h 2MEBM
exposure resulted in G2/M arrest; however, 48 h expo-
sure resulted in a sub-G1 peak accompanied with no
changes in the cell cycle distribution in the human
2MEBM-resistant cell line (A2780.140) derived from the
human ovarian carcinoma cell line (A2780) [13]. B-Cell
Lymphoma-2 Family Members (BCL-2) phosphorylation
has also been found to be induced by 2MEBM in MCF-
7 cells and correlates with a G2/M arrest [22]. Foster, et
al (2008) reported similar findings pertaining to the
decrease of 2MEBM-treated cells observed in the G1-
phase in this study [8,22,23]. Induction of apoptosis by
2MEBM in breast adenocarcinoma CAL51 cell line was
demonstrated by Wood, et al (2004) [24]. In this study
2MEBM caused a reduction in the mitochondrial mem-
brane potential, confirming the induction of apoptosis.
The mitochondrial membrane potential depolarization is
Number
of
events
Number
of
events
Number
of
events
Number
of
events
Absence of hydrogen peroxide 96%
Presence of hydrogen peroxide 4%
Absence of hydrogen peroxide 86%
Presence of hydrogen peroxide 14%
FL 1 Log FL 1 Log
A B
Figure 3 Hydrogen peroxide measurement (FL1 Log representing the hydrogen peroxide detected by flow cytometry) in 2ME2BM-
treated cells demonstrated a statistically insignificant increase to 14% when compared to the vehicle-treated cells (4%).
A
Number
of
events
Number
of
events
Number
of
events
Number
of
events
B
Presence of superoxide 1%
Absence of superoxide 99% Absence of superoxide 89%
Presence of superoxide 11%
FL 2 Log FL 2 Log
Figure 4 Superoxide production detection (FL2 Log representing the superoxide detected by flow cytometry) revealed an increase of
10% in the 2ME2BM-treated cells when compared to the vehicle-treated cells.
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pathway [20,25,26]. Our study suggests that 2-methox-
yestradiol-bis-sulphamate (2MEBM) influences the mito-
chondrial membrane potential minimally, thus the
involvement of the intrinsic pathway to a lesser extent.
Furthermore, exposure to 2MEBM revealed a sub-G1
peak. This is confirmed by studies conducted in our
laboratory where flow cytometry utilizing annexin V-
FITC demonstrated that 2MEBM induced apoptosis in
MCF-7 cells [18]. During apoptosis, the electrochemical
mitochondrial membrane gradient collapses [27-30].
The latter precipitates cell death through either the
release of molecules involved in apoptosis, or the loss of
mitochondrial functions essential for cell survival [31].
This study demonstrates the novel finding that
2MEBM exposure in the MCF-7 cell line resulted in
increased ROS production. However, the source and
processing of ROS and the role they play in 2MEBM-
induced growth inhibition and cell death remains to be
elucidated as no reports has been published on this
matter. It was previously reported that the precursor
molecule, 2ME2, inhibits superoxide dismutase and
increased ROS production in human leukaemia cells
[32]. 2ME2 also induces ROS generation in cell lines
including myeloid leukaemia U937 cells, myeloid leu-
kaemia HL-60 cell line, human acute T cell leukaemia
cells (Jurkat cells), HeLa cells and MCF-7 cells [32-35].
Azad, et al (2009) revealed that ROS can induce
autophagy by means of Atg4, catalase and the mito-
chondrial electron transport chain leading to both cell
survival and cell death and is a selective towards can-
cer treatment. ROS generation upregulates Beclin-1
expression by an unknown mechanism increasing the
occurrence of autophagy and hydrogen peroxide is
essential for starvation-induced autophagy and directly
targets Atg4 for oxidation and inactivates Atg4 indu-
cing autophagy [36]. In addition, upregulated mito-
chondrial matrix calcium leads to increased reactive
oxygen species production results in a reduction of the
mitochondrial membrane potential (permeability tran-
sition pore is triggered). The latter leads to cytochrome
c release from the mitochondria and subsequent acti-
vation of caspases leading to apoptosis [37,38]. Ling, et
al (2003) reported that upregulated reactive oxygen
species was accompanied by a reduction in the mito-
chondrial membrane potential and subsequent apopto-
sis [39]. Thus, the increased ROS production
accompanied with reduced mitochondrial potential
found in this study suggests that both of the above-
mentioned contribute to the apoptosis induced by
2MEBM. The novel finding regarding the in vitro
influence of 2MEBM on either of these reactive oxygen
species has not been reported as previously.
Conclusion
In conclusion, the aims of this project namely, to inves-
tigate the effects of 2MEBM exposure in the MCF-7 cell
line on cell cycle progression, reactive oxygen species
production and the possible induction of cell death were
achieved. 2MEBM exposure resulted in mitochondrial
membrane potential reduction and increased ROS pro-
duction and apoptosis. The data generated from this
project contributes to the known scientific knowledge
regarding the in vitro effects of 2MEBM, will possibly
lead to new possible in vitro targets for cancer therapies.
Future studies concerning the action mechanisms of
2MEBM is necessary to produce a better understanding
regarding the treatment of cancer and may possibly con-
tribute to the development and/or improvement of
novel chemotherapeutic agents.
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